UF startup and UF Innovate | Sid Martin Biotech resident client entrinsic bioscience (EBS), a company pioneering a next-generation protein modulation technology, announced that it has been granted U.S. Patent No. (USPN) 10,758,507 (‘507 patent) for novel therapeutic formulations in the treatment of a range of respiratory diseases with significant unmet medical needs.
EBS is a recognized leader in the development and commercialization of disruptive, science-derived biocatalyst technologies that are clinically proven to deliver better health outcomes in a broad range of wellness and therapeutic areas, including gut health, hydration, skin and respiratory health. The company is the first to discover that precise combinations of natural biocatalysts can act as cell signalers to modulate transport membrane proteins to improve cell function, and has acquired strong patent protection for novel combinations of its key compounds. The new patent expands the company’s global intellectual property portfolio to 12 key patent families leading to 6 U.S. patents, 43 global issued patents and 45 pending/published patent applications across 20 countries and regions, including the U.S., Europe, China, Japan and Korea.
EBS co-founder Dr. Sadasivan Vidyasagar and CEO Stephen Gatto recently received the 2020 Invention of the Year award by UF Innovate | Tech Licensing at the University of Florida for their work in COVID-19.Learn more about entrinsic bioscience Secures U.S. Patent Grant for Breakthrough Respiratory Disease Program.